Clinical Trial Update: An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II study assessing KL-A167 injection for safety and efficacy in relapsed or refractory classical Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• KL-A167

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Classical Hodgkin Lymphoma | Phase 2 | Status: COMPLETED